| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CIMT1; GLM1; NR1C3; Nuclear receptor subfamily 1 group C member 3; Peroxisome proliferator activated nuclear receptor gamma variant 1; Peroxisome proliferator activated receptor gamma 1; Peroxisome Proliferator Activated Receptor gamma; Peroxisome proliferator-activated receptor gamma; PPAR gamma; PPAR-gamma; PPARG; PPARG_HUMAN; PPARG1; PPARG2; PPARgamma. |
| Entrez GeneID | 5468 |
| WB Predicted band size | Calculated MW: 58 kDa; Observed MW: 53,57 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Recombinant Protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇关于PPPARγ抗体的参考文献及其摘要概括：
---
1. **文献名称**：*"Selective use of peroxisome proliferator-activated receptor γ (PPARγ) ligands in metabolic diseases"*
**作者**：Lehmann JM, et al.
**摘要**：该研究验证了多种PPARγ抗体的特异性，通过Western blot和免疫组化分析其在脂肪细胞分化中的作用，并探讨抗体在不同组织样本中的检测效果差异。
---
2. **文献名称**：*"Antibody-based profiling of PPARγ expression and activation in human tissues"*
**作者**：Tontonoz P, et al.
**摘要**：通过比较商业化的PPARγ抗体(如sc-7273和CST#2435)，评估其在人肝脏、脂肪及肿瘤组织中的灵敏度和交叉反应性，为选择可靠抗体提供实验依据。
---
3. **文献名称**：*"PPARγ agonists induce proteasomal degradation of PPARγ via a ubiquitination mechanism"*
**作者**：Hauser S, et al.
**摘要**：研究使用特异性PPARγ抗体(如Abcam ab45036)揭示罗格列酮等药物对PPARγ蛋白稳定性的影响，证实抗体在检测蛋白降解动态中的关键作用。
---
4. **文献名称**：*"Validation of PPARγ antibodies for immunohistochemical analysis of human macrophages"*
**作者**：Ricote M, et al.
**摘要**：针对巨噬细胞中PPARγ的免疫定位，筛选并验证高特异性抗体(如Santa Cruz E-8)，优化染色条件以减少非特异性背景信号。
---
以上文献涵盖抗体验证、应用场景及比较分析，可作为实验方法或机制研究的参考。
PPAR gamma (peroxisome proliferator-activated receptor gamma) is a nuclear receptor protein that plays a central role in regulating adipogenesis, lipid metabolism, glucose homeostasis, and inflammatory responses. As a transcription factor, it forms heterodimers with retinoid X receptors (RXRs) to modulate gene expression by binding to specific DNA sequences. PPAR gamma is highly expressed in adipose tissue and macrophages, making it a key therapeutic target for metabolic disorders like type 2 diabetes and obesity. Thiazolidinediones (TZDs), a class of insulin-sensitizing drugs, act as PPAR gamma agonists, underscoring its clinical relevance.
PPAR gamma antibodies are essential tools in biomedical research for detecting and quantifying the protein in various experimental settings, including Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate PPAR gamma's expression patterns, post-translational modifications (e.g., phosphorylation), and interactions with co-regulators in both physiological and pathological contexts. Researchers also use them to study PPAR gamma's role in cancer, cardiovascular diseases, and neurodegenerative disorders.
Commercial PPAR gamma antibodies are typically raised against specific epitopes, such as the N-terminal domain or ligand-binding domain. However, variability in specificity and cross-reactivity with other PPAR isoforms (e.g., PPAR alpha/delta) necessitates careful validation using knockout controls. Proper sample preparation and fixation are critical, as PPAR gamma's nuclear localization and tissue-specific expression require optimized protocols. These antibodies remain indispensable for advancing our understanding of metabolic regulation and drug development.
×
